featured
Long-Term Safety and Effectiveness of Trastuzumab Biosimilar PF-05280014 in Patients With HER2+ Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study
BioDrugs 2022 Jan 01;36(1)55-69, RK Li, E Tokunaga, H Adamchuk, V Vladimirov, E Yanez, KS Lee, I Bondarenko, A Vana, F Hilton, T Ishikawa, K Tajima, O LipatovFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.